Poly(lactide-co-glycolide) microspheres for MRI-monitored delivery of sorafenib in a rabbit VX2 model

Biomaterials

Volumn 61, Issue , 2015, Pages 299-306

  Chen, Jeane ^a,b   White, Sarah B ^b,c   Harris, Kathleen R ^b   Li, Weiguo ^b,d   Yap, Jonathan W T ^a   Kim, Dong Hyun ^b   Lewandowski, Robert J ^b   Shea, Lonnie D ^a,b,e   Larson, Andrew C ^a,b  

^a Northwestern University   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Hepatocellular carcinoma; Magnetic resonance imaging; Poly(lactide co glycolide); Sorafenib

Indexed keywords

EMULSIFICATION; IRON OXIDES; MAGNETIC NANOPARTICLES; MICROSPHERES; TUMORS;

HEPATOCELLULAR CARCINOMA; IRON OXIDE NANOPARTICLE; ORAL ADMINISTRATION; POLY LACTIDE-CO-GLYCOLIDE; POLY(LACTIDE-CO-GLYCOLIDE) MICROSPHERES; SORAFENIB; SYSTEMIC TOXICITIES; TRANSCATHETER ARTERIAL EMBOLIZATION;

MAGNETIC RESONANCE IMAGING;

MICROSPHERE; POLYGLACTIN; SORAFENIB; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; CONTRAST MEDIUM; FERRIC ION; FERRIC OXIDE; MICROCAPSULE; NICOTINAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL EMBOLISM; CAPILLARY DENSITY; CHEMOEMBOLIZATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; EXPERIMENTAL LIVER NEOPLASM; FOLLOW UP; IN VIVO STUDY; LIVER CELL CARCINOMA; NANOEMULSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PRIORITY JOURNAL; RABBIT MODEL; TUMOR MODEL; ADMINISTRATION AND DOSAGE; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DIFFUSION; DRUG MONITORING; LIVER NEOPLASMS; MICROCAPSULE; PATHOLOGY; PROCEDURES; RABBIT; TUMOR CELL LINE;

ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CAPSULES; CELL LINE, TUMOR; CONTRAST MEDIA; DIFFUSION; DRUG MONITORING; FERRIC COMPOUNDS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; NIACINAMIDE; PARTICLE SIZE; PHENYLUREA COMPOUNDS; POLYGLACTIN 910; RABBITS;

EID: 84939163121     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.05.010     Document Type: Article

References (29)

1. Bruix J., Gores G.J., Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014, 14(10). 2013-306627.
2. Forner A., Llovet J.M., Bruix J. Hepatocellular carcinoma. Lancet 2012, 379(9822):1245-1255.
3. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] 2013, France, Lyon, International Agency for Research on Cancer.
4. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010, 52(2):762-773.
5. Lencioni R. Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies. Oncology 2010, 78(Suppl. 1):107-112.
6. Lewis A.L., Dreher M.R. Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy. J. Control. Release 2012, 161(2):338-350.
7. Guan Y.S., He Q., Wang M.Q. Transcatheter arterial chemoembolization: history for more than 30 years. ISRN Gastroenterol. 2012, 480650(10):26.
8. Li X., et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J. Gastroenterol. 2004, 10(19):2878-2882.
9. Zhu A.X., et al. HCC and angiogenesis: possible targets and future directions. Nat. Rev. Clin. Oncol. 2011, 8(5):292-301.
10. Liu L., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66(24):11851-11858.
11. Sergio A., et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am. J. Gastroenterol. 2008, 103(4):914-921.
12. Weintraub J.L., Salem R. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science. J. Vasc. Interv. Radiol. 2013, 24(8):1123-1134.
13. Chao Y., et al. The combination of TACE (transcatheter arterial chemombolization) and sorafenib is well-tolerated and effective in Asian Patients with hepatocellular carcinoma: Final results of the START trial. Int. J. Cancer 2014, 36(6):1458-1467.
14. Llovet J.M., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359(4):378-390.
15. Keating G.M., Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009, 69(2):223-240. doi:10.2165/00003495-200969020-00006.
16. Lencioni R., et al. GIDEON (global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib): second interim analysis. Int. J. Clin. Pract. 2014, 68(5):609-617.
17. Lencioni R., et al. First interim analysis of the GIDEON (global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib) non-interventional study. Int. J. Clin. Pract. 2012, 66(7):675-683.
18. Ogasawara S., et al. Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol. Int. 2011, 5(3):850-856.
19. Cheng A.L., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10(1):25-34.
20. Qian J., et al. Application of poly-lactide-co-glycolide-microspheres in the transarterial chemoembolization in an animal model of hepatocellular carcinoma. World J. Gastroenterol. 2003, 9(1):94-98.
21. Chen J., et al. Poly(lactide-co-glycolide) microspheres for MRI-monitored transcatheter delivery of sorafenib to liver tumors. J. Control. Release 2014, 184(0):10-17.
22. Wang Y., et al. Preparation and structure of drug-carrying biodegradable microspheres designed for transarterial chemoembolization therapy. J. Biomater. Sci. Polym. Ed. 2015, 26(2):77-91.
23. Jain R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000, 21(23):2475-2490.
24. Wischke C., Schwendeman S.P. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int. J. Pharm. 2008, 364(2):298-327.
25. Blanchet B., et al. Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J. Pharm. Biomed. Analysis 2009, 49(4):1109-1114.
26. Chatziioannou A.N., et al. Transarterial embolization with sorafenib in animal livers: a pharmacokinetics study. J. Vasc. Interv. Radiol. 2013, 24(11):1657-1663. e1.
27. Gaba R.C., et al. Transarterial sorafenib chemoembolization: preliminary study of technical feasibility in a rabbit model. J. Vasc. Interv. Radiol. 2013, 24(5):744-750.
28. Varela M., et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J. Hepatol. 2007, 46(3):474-481.
29. Wu X.S., Wang N. Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid polymers. Part II: biodegradation. J. Biomater. Sci. Polym. Ed. 2001, 12(1):21-34.